Alpha Healthcare Acquisition CORP III: directors' dealings · United States · SEC (Form 4)

About Alpha Healthcare Acquisition CORP III

Alpha Healthcare Acquisition Corp. III was a U.S.-listed special purpose acquisition company (SPAC), incorporated in Delaware and based in New York at 1177 Avenue of the Americas, 5th Floor, New York, NY 10036. In its SEC filings, the company describes itself as a blank check company formed to pursue a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more targets. From inception, its search mandate was explicitly focused on the healthcare industry. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1842939/000119312522106907/d268885d10k.htm?utm_source=openai)) For investors, the key point is that Alpha Healthcare Acquisition Corp. III was not an operating healthcare company in the traditional sense. Before its business combination, it functioned as a capital-markets vehicle designed to bring a private business public on the U.S. NASDAQ market. Its equity story therefore centered on sponsor execution, deal sourcing, and transaction completion rather than recurring product sales or operating margins. The company’s business profile was tied to the SPAC structure, with no standalone commercial product portfolio of its own prior to the merger. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1842939/000119312522106907/d268885d10k.htm?utm_source=openai)) The most important recent development was the closing of its business combination with Carmell Therapeutics Corporation on July 14, 2023. According to the SEC, Alpha Healthcare Acquisition Corp. III changed its name to Carmell Therapeutics Corporation at closing, and the target company became a wholly owned subsidiary of the combined entity. The filing also states that ALPA ceased to be a shell company after the transaction. This is the defining event in the company’s recent history and materially changed the investment case from a pure healthcare SPAC to an operating healthcare platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1842939/000119312523190559/d513602d8k.htm?utm_source=openai)) From a competitive standpoint, the pre-combination Alpha Healthcare Acquisition Corp. III did not compete on product, technology, or distribution. Its competitive edge depended on the quality of its leadership team, access to capital, and ability to source an appealing healthcare target. That makes any analysis of the ticker prior to the merger very different from an analysis of the post-merger combined company. In other words, the historical SPAC should be viewed as a transaction vehicle, while the post-closing equity story must be evaluated through the operating business that emerged from the combination. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1842939/000119312523190559/d513602d8k.htm?utm_source=openai)) In short, Alpha Healthcare Acquisition Corp. III is best understood as a former healthcare-focused SPAC that traded on the NASDAQ in the United States and completed its transformative merger in July 2023. Its recent corporate history is dominated by that transaction, which redefined the issuer and ended its life as a shell company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1842939/000119312523190559/d513602d8k.htm?utm_source=openai))